Related Experiment Videos
[New antithrombotic agents in coronary disease]
1Service de cardiologie, hôpital de la Pitié-Salpêtrière, Paris, France.
La Revue De Medecine Interne
|January 1, 1997
Summary
New antiplatelet drugs, like GP IIb/IIIa antagonists, improve outcomes for unstable angina and high-risk PTCA. While effective acutely, long-term benefits and bleeding risks require careful consideration for antithrombotic therapy.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Context:
- Unstable angina and myocardial infarction require effective antithrombotic strategies.
- Optimal aspirin dosing and aspirin resistance remain areas of investigation.
- Low molecular weight heparins show comparable or superior efficacy to unfractionated heparin.
Purpose:
- To review the efficacy of various antithrombotic agents in acute coronary syndromes.
- To evaluate the role of new antiplatelet drugs, particularly GP IIb/IIIa antagonists, in periprocedural management.
- To discuss the benefits and risks of novel antithrombotic therapies.
Summary:
- Aspirin is a cornerstone, but optimal use is debated.
- Low molecular weight heparins offer advantages over unfractionated heparin in unstable angina.
- GP IIb/IIIa antagonists (e.g., c7E3) significantly reduce ischemic events in high-risk PTCA and unstable angina, with a notable reduction in death and myocardial infarction.
- While potent, GP IIb/IIIa antagonists increase hemorrhage risk; low-dose heparin regimens may mitigate this.
- Other agents like direct antithrombins have shown negative results, but oral antiplatelet drugs hold future promise.
Impact:
- GP IIb/IIIa antagonists have demonstrated immediate and sustained benefits in reducing mortality and myocardial infarction in high-risk patients.
- The development of potent antithrombotic drugs is improving the prognosis of acute coronary syndromes.
- Further research into oral antiplatelet agents may revolutionize future treatment paradigms.